The addition of ACE inhibitors, beta-blockers and mineralocorticoid antagonists has modified the evolution of heart failure, and the emergence of electrophysiology as well has added the use of ablation therapies and implantable cardio-defibrillators in the management of patients with Chagas cardiomyopathy. The gene discussed is ACE; the disease is heart failure.